Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis

Carcinogenesis

Volumn 26, Issue 4, 2005, Pages 741-751

  Wai, Philip Y ^a   Mi, Zhiyong ^a   Guo, Hongtao ^a   Sarraf Yazdi, Shiva ^a   Gao, Chengjiang ^a   Wei, Junping ^a   Marroquin, Carlos E ^a   Clary, Bryan ^a   Kuo, Paul C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; SMALL INTERFERING RNA; GELATINASE A; SIALOGLYCOPROTEIN; SPP1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL INVASION; CELL MOTILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; LIVER METASTASIS; MISMATCH REPAIR; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; COLON TUMOR; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; IN VITRO STUDY; LIVER TUMOR; METABOLISM; METASTASIS; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; COLONIC NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENE THERAPY; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; ORGAN SIZE; OSTEOPONTIN; RNA, SMALL INTERFERING; SIALOGLYCOPROTEINS;

EID: 17844388876     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgi027     Document Type: Article

References (69)

1. Parker, S.L., Tong, T., Bolden, S., and Wingo, P.A. (1996) Cancer statistics 1996. CA Cancer J. Clin., 46, 5-27.
2. Martin, R., Paty, P., Fong, Y., Grace, A., Cohen, A., Dematteo, R., Jarnagin, W. and Blumgart, L. (2003) Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J. Am. Coll. Surg., 197, 233-241.
3. Scheele, J., Stangl, R., Altendorf-Hofmann, A. and Gall, F.P. (1991) Indicators of prognosis after hepatic resection of colorectal secondaries. Surgery, 110, 13-29.
4. Senger, D.R., Wirth, D.F. and Hynes, R.O. (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell, 16, 885-893.
5. Denhardt, D.T. and Guo, X. (1993) Osteopontin: a protein with diverse functions. FASEB J., 7, 1475-1482.
6. Craig, A.M. and Denhardt, D.T. (1991) The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene, 100, 163-171.
7. Denhardt, D.T. and Noda, M. (1998) Osteopontin expression and function: role in bone remodeling. J. Cell Biochem. Suppl., 30-31, 92-102.
8. O'Regan, A. and Berman, J.S. (2000) Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol., 81, 373-390.
9. Weber, G.F. (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta, 155, 261-85.
10. Goodison, S., Urquidi, V. and Tarin, D. (1999) CD44 cell adhesion molecules. Mol. Pathol., 52, 189-196.
11. Denhardt, D.T., Noda, M., O'Regan, A.W., Pavlin, D. and Berman, J.S. (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest., 107, 1055-1061.
12. Weber, G.F., Ashkar, S., Glimcher, M.J. and Cantor, H. (1996) Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science, 271, 509-512.
13. Katagiri, Y.U., Sleeman, J., Fujii, H., Herrlich, P., Hotta, H., Tanaka, K., Chikuma, S., Yagita, H., Okumura, K., Murakami, M., Saiki, I., Chambers, A.F. and Uede, T. (1999) CD44 variants but not CD44s cooperate with beta 1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res., 59, 219-226.
14. Ashkar, S., Weber, G.F., Panoutsakopoulou, V., Sanchirico, M.E., Jansson, M., Zawaideh, S., Rittling, S.R., Denhardt, D.T., Glimcher, M.J. and Cantor, H. (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science, 287, 860-864.
15. Gao, C., Guo, H., Downey, L., Marroquin, C., Wei, J. and Kuo, P.C. (2003) Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis, 24, 1871-1878.
16. Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, A.F., Szabo, M., Cantor, A., Coppola, D. and Yeatman, T.J. (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl Cancer Inst., 94, 513-521.
17. Yeatman, T.J. and Chambers, A.F. (2003) Osteopontin and colon cancer progression. Clin. Exp. Metastasis, 20, 85-90.
18. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
19. Caplen, N.J., Parrish, S., Imani, F., Fire, A. and Morgan, R.A. (2001) Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl Acad. Sci. USA, 98, 9742-9747.
20. Corbett, T.H., Griswold, D.P., Jr, Roberts, B.J., Peckham, J.C. and Schabel, F.M., Jr. (1975) Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res., 35, 2434-2439.
21. Ikubo, A., Aoki, Y., Nagai, E. and Suzuki, T. (1999) Highly metastatic variant of a mouse colon carcinoma cell line, LM17 and its response to GM-CSF gene therapy. Clin. Exp. Metastasis, 17, 849-855.
22. Morikawa, K., Walker, S.M., Nakajima, M., Pathak, S., Jessup, J.M. and Fidler, I.J. (1988) Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res., 48, 6863-6871.
23. Ishikawa, T., Yoshida, N., Higashihara, H., Inoue, M., Uchiyama, K., Takagi, T., Handa, O., Kokura, S., Naito, Y., Okanoue, T. and Yoshikawa, T. (2003) Different effects of constitutive nitric oxide synthase and heme oxygenase on pulmonary or liver metastasis of colon cancer in mice. Clin. Exp. Metastasis, 20, 445-450.
24. Myslinski, E., Ame, J.C., Krol, A. and Carbon, P. (2001) An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene. Nucleic Acids Res., 29, 2502-2509.
25. Gao, C., Guo, H., Wei, J., Mi, Z., Wai, P. and Kuo, P.C. (2004) S-nitrosylation of heterogeneous nuclear ribonucleoprotein A/B regulates Osteopontin transcription in endotoxin-stimulated murine macrophages. J. Biol. Chem., 279, 11236-1143.
26. Sieuwerts, A.M., Klijn, J.G. and Foekens, J.A. (1997) Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: influences of the ability of cells to migrate through the filter membrane. Clin. Exp Metastasis, 15, 53-62.
27. Repesh, L.A. (1989) A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis, 9, 192-208.
28. Tuck, A.B., O'Malley, F.P., Singhal, H., Harris, J.F., Tonkin, K.S., Kerkvliet, N., Saad, Z., Doig, G.S. and Chambers, A.F. (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer, 79, 502-508.
29. Tuck, A.B., O'Malley, F.P., Singhal, H., Tonkin, K.S., Harris, J.F., Bautista, D. and Chambers, A.F. (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med., 121, 578-584.
30. Tuck, A.B., Arsenault, D.M., O'Malley, F.P., Hota, C., Ling, M.C., Wilson, S.M. and Chambers, A.F. (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 18, 4237-4246.
31. Ue, T., Yokozaki, H., Kitadai, Y., Yamamoto, S., Yasui, W., Ishikawa, T. and Tahara, E. (1998) Co-expression of Osteopontin and CD44v9 in gastric cancer. Int. J. Cancer, 79, 127-132.
32. Shijubo, N., Uede, T., Kon, S., Maeda, M., Segawa, T., Imada, A., Hirasawa, M. and Abe, S. (1999) Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med., 160, 1269-1273.
33. Chambers, A.F., Wilson, S.M., Kerkvliet, N., O'Malley, F.P., Harris, J.F. and Casson, A.G. (1996) Osteopontin expression in lung cancer. Lung Cancer, 15, 311-323.
34. Thalmann, G.N., Sikes, R.A., Devoll, R.E., Kiefer, J.A., Markwalder, R., Klima, I., Farach-Carson, C.M., Studer, U.E. and Chung, L.W. (1999) Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res., 5, 2271-2277.
35. Gotoh, M., Sakamoto, M., Kanetaka, K., Chuuma, M. and Hirohashi, S. (2002) Overexpression of osteopontin in hepatocellular carcinoma. Pathol. Int., 52, 19-24.
36. Pan, H.W., Ou, Y.H., Peng, S.Y., Liu, S.H., Lai, P.L., Lee, P.H., Sheu, J.C., Chen, C.L. and Hsu, H.C. (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 98, 119-127.
37. Das, R., Mahabeleshwar, G.H. and Kundu, G.C. (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem., 278, 28593-28606
38. Rangaswami, H., Bulbule, A. and Kundu, G.C. (2004) Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/ IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem., 279, 38921-38935.
39. Senger, D.R., Ledbetter, S.R., Claffey, K.P., Papadopoulos-Sergiou, A., Peruzzi, C.A. and Detmar, M. (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am. J. Pathol., 149, 293-305.
40. Leduc, E.H. (1959) Metastasis of transplantable hepatomas from the spleen to the liver in mice. Cancer Res., 19, 1091-1095.
41. Giavazzi, R., Jessup, J.M., Campbell, D.E., Walker, S.M. and Fidler, I.J. (1986) Experimental nude mouse model of human colorectal cancer liver metastases. J. Natl Cancer Inst., 77, 1303-1308.
42. Reeder, J.A., Gotley, D.C., Walsh, M.D., Fawcett, J. and Antalis, T.M. (1998) Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Res., 58, 3719-3726.
43. Kitakata, H., Nemoto-Sasaki, Y., Takahashi, Y., Kondo, T., Mai, M. and Mukaida, N. (2002) Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res., 62, 6682-6687.
44. Samani, A.A., Chevet, E., Fallavollita, L., Galipeau, J. and Brodt, P. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res., 64, 3380-3385.
45. Yu, H.K., Kim J.S., Lee, H.J., Ahn, J.H., Lee, S.K., Hong, S.W. and Yoon, Y. (2004) Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles. Cancer Res., 64, 7092-7098.
46. Radinsky, R., Risin, S. Fan, D. Dong, Z., Bielenberg, D., Bucana, C.D. and Fidler, I.J. (1995) Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res., 1, 19-31.
47. Fidler, I.J. (1991) Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev., 10, 229-243.
48. Tan, M.H., Holyoke, E.D. and Goldrosen, M.H. (1977) Murine colon adenocarcinoma: syngeneic orthotopic transplantation and subsequent hepatic metastases. J. Natl Cancer Inst., 59, 1537-1544.
49. Ozawa, S., Lu, W., Bucana, C.D., Kanayama, H.O., Shinohara, H., Fidler, I.J. and Dong, Z. (2003) Regression of primary murine colon cancer and occult liver metastasis by intralesional injection of lyophilized preparation of insect cells producing murine interferon-beta. Int. J. Oncol., 22, 977-984.
50. Khanna, C. and Hunter, K. (2005) Modeling metastasis in vivo. Carcinogenesis, 26, 513-523.
51. Mathews, M.B., Bernstein, R.M., Franza, B.R., Jr and Garrels, J.I. (1984) Identity of the proliferating cell nuclear antigen and cyclin. Nature, 309, 374-376.
52. Ben-Izhak, O., Bar-Chana, M., Sussman, L., Dobiner, V., Sandbank, J., Cagnano, M., Cohen, H. and Sabo, E. (2002) Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology, 41, 519-525.
53. Kelman, Z. (1997) PCNA structure, functions and interactions. Oncogene, 14, 629-640.
54. Scholzen, T. and Gerdes, J. (2000) The Ki-67 protein: From the known and the unknown. J. Cell Physiol., 182, 311-322.
55. Liu, M., Lawson, G., Delos, M., Jamart, J., Ide, C., Coche, E., Weynand, B., Desuter, G., Hamoir, M., Remacle, M. and Marbaix, E. (2003) Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations. Head Neck, 25, 280-288.
56. Veronese, S.M., Maisano, C. and Scibilia, J. (1995) Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res., 15, 2717-2722.
57. Ishida, H., Miwa, H., Tatsuta, M., Masutani, S., Imamura, H., Shimizu, J., Ezumi, K., Kato, H., Kawasaki, T., Furukawa, H. and Kawakami, H. (2004) Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer. Cancer Lett., 207, 109-115.
58. Petrowsky, H., Sturm, I., Graubitz, O., Kooby, D.A., Staib-Sebler, E., Gog, C., Kohne, C.H., Hillebrand, T., Daniel, P.T., Fong, Y. and Lorenz, M. (2001) Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur. J. Surg. Oncol. 27, 80-87.
59. Aznavoorian, S., Murphy, A.N., Stetler-Stevenson, W.G. and Liotta, L.A. (1993) Molecular aspects of tumor cell invasion and metastasis. Cancer, 71, 1368-1383.
60. Murphy, G. and Gavrilovic, J. (1999) Proteolysis and cell migration: creating a path? Curr. Opin. Cell Biol. 11, 614-621.
61. Tuck, A.B., Hota, C. and Chambers, A.F. (2001) Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res. Treat., 70, 197-204.
62. Philip, S. and Kundu, G.C. (2003) Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J. Biol. Chem., 278, 14487-14497.
63. Friedl, P. and Wolf, K. (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer, 3, 362-374.
64. Tuck, A.B., Elliott, B.E., Hota, C., Tremblay, E. and Chambers, A.F. (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell Biochem., 78, 465-475.
65. Tuck, A.B., Hota, C., Wilson, S.M. and Chambers, A.F. (2003) Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene, 22, 1198-1205.
66. Zohar, R., Suzuki, N., Suzuki, K., Arora, P., Glogauer, M., McCulloch, C.A. and Sodek, J. (2000) Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J. Cell Physiol., 184, 118-130.
67. Hijiya, N., Setoguchi, M., Matsuura, K., Higuchi, Y., Akizuki, S. and Yamamoto, S. (1994) Cloning and characterization of the human osteopontin gene and its promoter. Biochem. J., 303, 255-262.
68. Wai, P.Y. and Kuo, P.C. (2004) The role of osteopontin in tumor metastasis. J. Surg. Res., 121, 228-241.
69. Denhardt, D.T., Mistretta, D., Chambers, A.F., Krishna, S., Porter, J.F., Raghuram, S. and Rittling, S.R. (2003) Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin. Exp. Metastasis, 20, 77-84.